Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOFEM: Propranolol-assisted traumatic memory reactivation for PTSD in women victims of violence
2025-523107-30-01Phase 3Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of propranolol in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Primary PTSD symptom severity. Planned start Jun 2026; status: authorised.
02
Drugs
propranolol
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2025-523107-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523107-30-01.